Mylan Specialty L.P.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$21.3M
Doctors Paid
43,129
Transactions
180,892
2024 Total
$2.9M
Payment Breakdown by Category
Research$10.8M (50.5%)
Food & Beverage$3.5M (16.4%)
Consulting$1.4M (6.4%)
Travel$709,985 (3.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $10.8M | 982 | 50.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4.6M | 3,482 | 21.6% |
| Food and Beverage | $3.5M | 172,044 | 16.4% |
| Consulting Fee | $1.4M | 1,055 | 6.4% |
| Travel and Lodging | $709,985 | 3,024 | 3.3% |
| Grant | $193,605 | 10 | 0.9% |
| Space rental or facility fees (teaching hospital only) | $72,199 | 48 | 0.3% |
| Education | $70,685 | 244 | 0.3% |
| Charitable Contribution | $29,100 | 3 | 0.1% |
Payments by Type
Research
$10.8M
982 transactions
General
$10.6M
179,910 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) | $5.9M | 0 | 696 |
| A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel?Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) | $938,268 | 0 | 94 |
| SB16A1.07 | $758,760 | 0 | 12 |
| Revefenacin in Acute Respiratory Insufficiency in COPD (RARICO) | $382,779 | 0 | 17 |
| XULA-TD-1004 | $350,011 | 0 | 4 |
| Prevalence of Impairments in Cognitive Function and Manual Dexterity in Out-patients with COPD and Associations with Correct Inhaler Techniques | $335,900 | 0 | 5 |
| DOM-19001 | $285,000 | 1 | 8 |
| Emergency Department Management of Patients with Food or Insect Sting Allergies: 38th Multicenter Airway Research Collaboration (MARC-38) Study | $252,555 | 0 | 1 |
| XULA-TD-1005 | $205,605 | 0 | 5 |
| TWRL-TD-1001 | $165,501 | 0 | 6 |
| ROTI-TD-1005 | $154,478 | 0 | 5 |
| Research_A Phase 3b, 28-day, Randomized, Active-Controlled, Parallel Group Study to Evaluate the Safety and Tolerability of Nebulized Revefenacin administered before Nebulized Formoterol Fumarate (PER | $122,083 | 1 | 15 |
| Differentiating the Effects of Long-acting Bronchodilators Administered by Nebulizer versus Dry Powder Inhaler in Symptomatic Patients with Chronic Obstructive Pulmonary Disease | $109,886 | 0 | 9 |
| Development of an Electronic Registry to Determine Prevalence and Characteristics of Anaphylaxis and Epinephrine Use | $80,614 | 0 | 1 |
| Research_Phase 3b, 28-day, Randomized, Active-Controlled, Parallel Group Study to Evaluate Safety and Tolerability of Nebulized Revefenacin administered before Nebulized Formoterol Fumarate | $80,032 | 1 | 23 |
| Subramaniam-The Effect of Intraoperative Continuous Remifentanil Infusion on Glycemic Response and Variability | $69,375 | 0 | 1 |
| PIFR 2 | $52,500 | 0 | 37 |
| A qualitative study to understand patient & social factors related to nebulizer use at the transition of care in COPD | $51,576 | 0 | 4 |
| CTBM100CUS03T | $50,586 | 0 | 1 |
| Improving Food Allergy Verification and EpiPen Auto-Injector Access in the Chicago Public Schools | $50,000 | 0 | 1 |
| The Effect of Intraoperative Continuous Remifentanil Infusion on Glycemic Response and Variability | $41,625 | 0 | 2 |
| Long-acting Bronchodilators Administered by Nebulizer vs Dry Powder Inhaler in Symptomatic Patients with Chronic Obstructive Pulmonary Disease | $41,572 | 0 | 2 |
| Nebulized LAMA Program in a Healthcare System | $40,000 | 0 | 1 |
| Elucidating the Epidemiology of Anaphylaxis in the Elderly | $37,396 | 0 | 2 |
| Understanding Anaphalaxis in Camps: A study measuring demographics, knowledge, and incidence of allergic reactions | $33,982 | 0 | 1 |
| Elucidating the Epidemiology of Anaphylaxis in the Eldery | $30,596 | 0 | 2 |
| National Registry of Food Allergy Treatment | $30,000 | 0 | 2 |
| PROSPECTIVE RANDOMIZED 12-WEEK CONTROLLED STUDY OF VISUAL FIELD CHANGE IN SUBJECTS WITH PARTIAL SEIZURES RECEIVING PREGABALIN OR PLACEBO | $29,542 | 0 | 4 |
| Identifying Clinically Relevant PIF Cutoffs | $28,800 | 0 | 1 |
| Understanding Patients Practices for Keeping Multiple Epinephrine Auto-injectors in Multiple Locations | $25,000 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors — Page 2
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Dr. Alexey Knyazhitskiy, M.d, M.D | Internal Medicine | Taunton, MA | $58,631 | $0 |
| Dr. Josephine Mei, Md, MD | Sleep Medicine | Louisville, KY | $56,820 | $0 |
| Dr. Amit Narula, D.o, D.O | Internal Medicine | Westminster, MD | $56,433 | $0 |
| Thomas Siler, Md, MD | Pulmonary Disease | Saint Charles, MO | $54,915 | $0 |
| Dr. Daria Lee, M.d, M.D | Pulmonary Disease | Fort Wayne, IN | $53,930 | $0 |
| Craig Thurm, Md, MD | Critical Care Medicine | Jamaica, NY | $52,515 | $0 |
| Unknown Provider | — | — | $52,497 | $0 |
| Jeffrey Cary, Md, MD | Pulmonary Disease | Seattle, WA | $50,310 | $0 |
| Tapas Bandyopadhyay, Md, MD | Critical Care Medicine | West Hartford, CT | $50,259 | $0 |
| William Frazier, Md, MD | Critical Care Medicine | Canton, MS | $49,328 | $0 |
| Dr. Gregory Mauldin, Md, MD | Pulmonary Disease | Snellville, GA | $48,944 | $0 |
| Dr. Mir-Omar Ali, Md, MD | Critical Care Medicine | Clayton, NC | $48,394 | $0 |
| Igor Barjaktarevic, M.d., M.sc, M.D., M.SC | Critical Care Medicine | Los Angeles, CA | $47,607 | $0 |
| Shyamsunder Subramanian, Md, MD | Critical Care Medicine | Tracy, CA | $46,740 | $0 |
| Dr. Alvaro Aranda- Rodriguez, Md, MD | Pulmonary Disease | Guaynabo, PR | $45,119 | $0 |
| Harold Haller, Md, MD | Pulmonary Disease | Louisville, KY | $44,850 | $0 |
| Dr. Hoang Le, M.d, M.D | Pulmonary Disease | Fountain Valley, CA | $43,227 | $0 |
| Warren Botnick, M.d, M.D | Critical Care Medicine | Natchitoches, LA | $42,018 | $0 |
| Patrice Collins, M.d, M.D | Anesthesiology | Princeton, NJ | $41,800 | $0 |
| Jill Ohar, Md, MD | Pulmonary Disease | Winston Salem, NC | $40,817 | $0 |
| Tala'at Al-Shuqairat, Md, MD | Critical Care Medicine | Salem, UT | $40,344 | $0 |
| Dr. Salim Surani, M.d, M.D | Pulmonary Disease | Corpus Christi, TX | $38,690 | $0 |
| Robert Benkert, Md, MD | Pulmonary Disease | Wheat Ridge, CO | $38,043 | $0 |
| Sridhar Dasari, Md, MD | Pulmonary Disease | Abington, MA | $37,298 | $0 |
| Dr. Gordon Warner, Md, MD | Pastoral | Cullman, AL | $35,481 | $0 |
Ad
Top Products
- Yupelri $9.2M
- YUPELRI $7.6M
Associated Products (9)
- Yupelri $9.3M
- YUPELRI $7.6M
- Dymista $1.1M
- EpiPen $504,345
- Ultiva $189,341
- Perforomist $148,869
- TOBI Podhaler $119,146
- Tobi Podhaler $24,700
- GLATIRAMER ACETATE $12,536
Payment Categories
- Food & Beverage $3.5M
- Consulting $1.4M
- Travel & Lodging $709,985
- Research $10.8M
About Mylan Specialty L.P.
Mylan Specialty L.P. has made $21.3M in payments to 43,129 healthcare providers, recorded across 180,892 transactions in the CMS Open Payments database. In 2024, the company paid $2.9M. The top product by payment volume is Yupelri ($9.2M).
Payments were distributed across 231 medical specialties. The top specialty by payment amount is Pulmonary Disease ($3.0M to 2,872 doctors).
Payment categories include: Food & Beverage ($3.5M), Consulting ($1.4M), Research ($10.8M), Travel & Lodging ($709,985).
Mylan Specialty L.P. is associated with 9 products in the CMS Open Payments database, including Yupelri, YUPELRI, and Dymista.